<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anesthesia for the patient with myasthenia gravis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anesthesia for the patient with myasthenia gravis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anesthesia for the patient with myasthenia gravis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Riki Kveraga, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Pawlowski, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie B Jones, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H697570583"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myasthenia gravis (MG) is an autoimmune disorder characterized by fatigable weakness of skeletal muscles. Weakness results from an antibody-mediated immunologic attack directed at acetylcholine receptors (or receptor-associated proteins) in the postsynaptic membrane of the neuromuscular junction.</p><p>Anesthetic concerns for patients with MG include the interactions among the disease, the disease treatment, and the medications used for anesthesia, particularly neuromuscular blocking agents (NMBAs). Patients with MG are unpredictably sensitive to nondepolarizing NMBAs and are resistant to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, a depolarizing NMBA.</p><p>Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction, with antibodies directed against the presynaptic voltage-gated calcium channels. It is often associated with an underlying malignancy, most commonly small cell lung cancer, though it is also associated with other autoimmune processes. Patients with LEMS are very sensitive to both depolarizing and nondepolarizing NMBAs.</p><p>This topic will discuss the anesthetic management of patients with MG and LEMS. Diagnosis, clinical manifestations, and management of MG and LEMS are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5134.html" rel="external">"Lambert-Eaton myasthenic syndrome: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H697570597"><span class="h1">PREOPERATIVE EVALUATION</span><span class="headingEndMark"> — </span>Preoperative preparation for elective surgery for patients with MG should be coordinated with the patient's neurologist. Elective surgery should be performed during a stable phase of the disease, when the patient requires minimal immunomodulatory medication or glucocorticoids, to minimize the chance of postoperative myasthenic crisis. In addition to routine preoperative evaluation, assessment of patients with MG should focus on bulbar and respiratory symptoms, as well as prior history of exacerbations or myasthenic crisis. Surgery should be scheduled as early in the day as possible, when the patient is strongest [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H578344649"><span class="h2">History</span><span class="headingEndMark"> — </span>Patients with MG should be evaluated preoperatively for the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Bulbar symptoms (eg, dysphagia, dysarthria, nasal speech, or low-intensity speech), which may predispose to aspiration</p><p class="bulletIndent1"><span class="glyph">●</span>History of myasthenic crisis and need for endotracheal intubation</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory muscle weakness, shortness of breath, and dyspnea</p><p class="bulletIndent1"><span class="glyph">●</span>MG therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Associated diseases, including other autoimmune diseases (eg, thyroiditis, rheumatoid arthritis, systemic lupus erythematosus)</p><p></p><p>Patients having thymectomy for thymic mass may be at risk for airway compromise with induction of anesthesia. Imaging studies (eg, chest computed tomography) should be reviewed. (See  <a class="medical medical_review" href="/d/html/94259.html" rel="external">"Anesthesia for patients with an anterior mediastinal mass"</a>.)</p><p class="headingAnchor" id="H16669268"><span class="h2">Prediction of postoperative myasthenic crisis</span></p><p class="headingAnchor" id="H712810779"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>A number of authors have attempted to define risk factors for postoperative myasthenic crisis. Retrospective studies including patients with MG who underwent transsternal thymectomy or videoscopic thymectomy using a variety of anesthetic strategies have reported associations between a number of preoperative factors and the need for postoperative ventilation. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Vital capacity &lt;2 to 2.9 L [<a href="#rid2">2-4</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of MG (greater than six years) [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">Pyridostigmine</a> dose &gt;750 mg/day [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>History of chronic pulmonary disease [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative bulbar symptoms [<a href="#rid5">5-8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>History of myasthenic crisis [<a href="#rid5">5,8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Intraoperative blood loss &gt;1000 mL [<a href="#rid5">5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Serum antiacetylcholine receptor antibody &gt;100 nmol/mL [<a href="#rid5">5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>More pronounced decremental response (18 to 20 percent) on low-frequency repetitive nerve stimulation [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H11795343"><span class="h3">Preoperative pulmonary evaluation</span><span class="headingEndMark"> — </span>In consultation with the patient's neurologist, pulmonary function testing (PFT) may be performed for patients with MG who will receive general anesthesia with the use of neuromuscular blocking agents (NMBAs) to assess optimization, to help establish a baseline for extubation, and to help plan for the level of postoperative care.</p><p>The available literature is insufficient to determine the level of preoperative pulmonary dysfunction that would predict the need for postoperative ventilation or the risk of myasthenic crisis for a specific surgical procedure. A retrospective review of patients who underwent video-assisted thoracoscopic thymectomy reported no difference in the need for intensive care unit admission for patients with a preoperative vital capacity &lt;2 L compared with those with vital capacity &gt;2 L [<a href="#rid8">8</a>], although previous studies had found an association [<a href="#rid2">2,3</a>]. A retrospective review of patients with MG who underwent videoscopic thymectomy found that patients who had myasthenic crisis after surgery had lower forced vital capacity (FVC) than those who did not (2.1 versus 3.0 L) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H578344708"><span class="h2">Myasthenia gravis treatments</span><span class="headingEndMark"> — </span>Patients with MG are treated with one or more medical therapies: symptomatic treatment (ie, anticholinesterase agents), chronic immunomodulating treatments (ie, glucocorticoids and other immunosuppressive medication), and rapid immunomodulating treatments for symptom exacerbations (ie, plasmapheresis and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> [IVIG]). These therapies are discussed separately. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Overview of therapies'</a>.)</p><p class="headingAnchor" id="H578344733"><span class="h3">Anticholinesterase agents</span><span class="headingEndMark"> — </span>We suggest continuing anticholinesterase agents (ie, <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a> or <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>) up to and including the morning of surgery, recognizing that the response to both depolarizing and nondepolarizing NMBAs may be modified by these medications. In addition, the response to NMBA reversal agents may be unpredictable or insufficient. Patients with MG who are maintained on anticholinesterases can be quite sensitive to discontinuation of the medication, with development of respiratory and bulbar weakness if medication is withheld. (See <a class="local">'Neuromuscular blocking agents'</a> below.)</p><p>A study of 14 patients with MG scheduled to undergo thymectomy randomly assigned patients to receive their usual dose of <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a> on the morning of surgery or to discontinue the medication after the last dose the night prior to surgery. Three of seven (43 percent) patients who did not receive pyridostigmine on the morning of surgery complained of respiratory discomfort while waiting for surgery (including two who required rescue IV <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> preoperatively), compared with none of the patients who received their usual medication. The study reported resistance to and delayed onset of block with <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> administration in patients who took their morning dose of pyridostigmine, but full reversal of neuromuscular block was accomplished in all patients [<a href="#rid9">9</a>].</p><p><a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">Pyridostigmine</a>, the most commonly used anticholinesterase for MG, has a rapid onset of action (15 to 30 minutes), with peak action at approximately two hours, and its effects last for three to four hours, sometimes longer. The timing and dose of medication is individualized based on the patient's symptoms. The starting dose is often 30 mg orally (per os [PO]), with the dose then titrated to effect. If IV dosing is necessary in the perioperative period, the IV dose is approximately one-thirtieth the oral dose (ie, 1 mg IV is equivalent to 30 mg PO).</p><p class="headingAnchor" id="H578344852"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Patients whose treatment for MG includes glucocorticoids may be at risk for hypothalamic pituitary axis suppression and adrenal insufficiency in the perioperative period, and may require administration of stress-dose glucocorticoids, depending on the surgical procedure  (<a class="graphic graphic_table graphicRef69479" href="/d/graphic/69479.html" rel="external">table 1</a>). These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/146.html" rel="external">"The management of the surgical patient taking glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Metabolic and endocrine effects'</a>.)</p><p>The following approach applies to patients without underlying primary adrenal insufficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are currently taking glucocorticoids should take their usual daily dose of glucocorticoid (or the parenteral equivalent). Stress dose glucocorticoids should not routinely be administered before induction of anesthesia for these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have taken glucocorticoids of any dose for less than three weeks, daily <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> less than 5 mg or its equivalent  (<a class="graphic graphic_table graphicRef64138" href="/d/graphic/64138.html" rel="external">table 2</a>) for any duration, or less than 10 mg prednisone or its equivalent every other day in the six months prior to surgery are not at risk for hypothalamic-pituitary-adrenal axis suppression, and they should not receive stress dose glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have taken doses of 5 mg or more of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (or its equivalent) for more than three weeks within six months of surgery or who appear Cushingoid should either receive stress dose glucocorticoids before induction of anesthesia, or they should have their hypothalamic pituitary axis tested preoperatively  (<a class="graphic graphic_table graphicRef69479" href="/d/graphic/69479.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H1203236482"><span class="h3">Immunotherapy</span><span class="headingEndMark"> — </span>Long-term immunotherapy for MG may include administration of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. Additionally, several newer biologics have been approved for use in MG. There are no published data to guide management of these immunomodulatory drugs around the time of surgery. Although parenteral substitution is possible for both cyclosporine and azathioprine, they likely can be held on the morning of surgery given the long duration of effect. The time course of immunomodulatory effects of these medications suggests that perioperative drug interruptions are not likely to cause significant symptomatic effect. (See  <a class="medical medical_review" href="/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis"</a>.)</p><p>Preoperative laboratory assessment including electrolytes, renal and hepatic function tests, and complete blood count should be performed for patients taking these medications. While <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> injected at supratherapeutic doses has been shown to reverse existing nondepolarizing neuromuscular block in animals, this is not likely a clinically relevant effect in humans [<a href="#rid10">10-12</a>]. Prior administration of azathioprine has been shown to have no effect on dose response curves of nondepolarizing neuromuscular blockade.</p><p class="headingAnchor" id="H578344904"><span class="h3">Rapid immunomodulating therapy</span><span class="headingEndMark"> — </span>Plasmapheresis and IV <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) are rapid therapies that work quickly (over days), but the benefits are only short-term (weeks). They are used preoperatively before thymectomy or other surgery, as a bridge to slower-acting immunotherapies, during myasthenic crisis, and periodically to maintain remission for patients with MG that is not well controlled otherwise. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Plasma exchange and IVIG as rescue or bridge therapies'</a>.)</p><p class="headingAnchor" id="H697570627"><span class="h1">ANESTHESIA MANAGEMENT</span></p><p class="headingAnchor" id="H2557340177"><span class="h2">Principles of the management of anesthesia for patients with MG</span></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> is not available, avoid neuromuscular blocking agents (NMBAs) if at all possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whenever NMBAs are used in patients with MG, a quantitative neuromuscular monitor should be used to assess reversal and a train of four ratio &gt; 0.9 confirmed prior to extubation.(See <a class="local">'Neuromuscular blocking agents'</a> below and  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Qualitative versus quantitative monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of ultrashort- or short-acting sedatives, hypnotics, and anesthetic agents to minimize respiratory depression on emergence from anesthesia.</p><p></p><p class="headingAnchor" id="H578345008"><span class="h2">Premedication</span><span class="headingEndMark"> — </span>In many cases, premedication with sedatives can be avoided by reassurance and explanation of expected procedures. If premedication is necessary, the smallest effective dose should be administered incrementally (eg, <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> 0.5 mg intravenously [IV]), with continuous monitoring for signs of bulbar weakness and respiratory compromise.</p><p class="headingAnchor" id="H578345015"><span class="h2">Choice of anesthetic technique</span><span class="headingEndMark"> — </span>When possible, local or regional anesthesia should be used. Regional anesthesia should be considered for peripheral procedures that can be done with relatively low-level neuraxial anesthesia, either epidural or spinal, or with peripheral nerve blocks. If local anesthetics are used, amide local anesthetics (<a class="drug drug_general" data-topicid="9873" href="/d/drug information/9873.html" rel="external">ropivacaine</a>, <a class="drug drug_general" data-topicid="9610" href="/d/drug information/9610.html" rel="external">mepivacaine</a>, <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>) should be chosen over esters for patients who take anticholinesterases [<a href="#rid13">13</a>]. Anticholinesterases, used for treatment for patients with MG, may theoretically impair the hydrolysis of ester local anesthetics (eg, <a class="drug drug_general" data-topicid="9245" href="/d/drug information/9245.html" rel="external">chloroprocaine</a>) and result in prolonged block, although there are no studies providing evidence of this effect.</p><p>Additional concerns specific to the patient with MG include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuraxial anesthesia</strong> – Midthoracic or higher levels of neuraxial anesthesia can result in paralysis of accessory muscles of breathing. Patients with preoperative respiratory compromise or bulbar weakness may not tolerate such levels of motor block. (See  <a class="medical medical_review" href="/d/html/89517.html" rel="external">"Overview of neuraxial anesthesia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brachial plexus blocks</strong> – In most patients, supraclavicular and interscalene brachial plexus blocks for upper-extremity surgery paralyze the diaphragm on the side of the block by blocking the phrenic nerve, potentially for many hours, which may not be tolerated by patients with respiratory compromise. (See  <a class="medical medical_review" href="/d/html/126189.html" rel="external">"Interscalene block procedure guide", section on 'Complications'</a> and  <a class="medical medical_review" href="/d/html/100069.html" rel="external">"Upper extremity nerve blocks: Techniques", section on 'Side effects and complications of supraclavicular block'</a>.)</p><p></p><p class="headingAnchor" id="H16669578"><span class="h2">Induction and maintenance of anesthesia</span><span class="headingEndMark"> — </span>A variety of strategies have been used for induction and maintenance of anesthesia for patients with MG. The overarching goals are to prevent prolonged effects on respiratory and bulbar muscles and to allow rapid recovery at the end of surgery. NMBAs should be avoided when possible [<a href="#rid14">14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhalation agents </strong>–<strong> </strong>The potent inhaled anesthetics (<a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, halothane) provide dose-dependent neuromuscular relaxation in patients with MG [<a href="#rid15">15-18</a>]. These agents may provide adequate relaxation for endotracheal intubation and surgery, possibly equivalent to the level of relaxation achieved with NMBAs in normal patients. There are many reports of thymectomy performed with the use of potent inhalation agents, without the need for NMBAs [<a href="#rid8">8,18,19</a>]. Muscle strength recovers as the inhalation agent is eliminated, without the need for reversal agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous agents </strong>– IV anesthetics have also been used for induction and maintenance of anesthesia for patients with MG, with or without small doses of NMBAs. <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is most commonly used for induction of anesthesia, as it provides rapid onset, short duration of action, and suppression of airway reflexes. Total IV anesthesia with infusions of propofol and <a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">remifentanil</a> has been described for anesthesia without the use of NMBAs for patients with MG undergoing thymectomy [<a href="#rid8">8,20,21</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">Remifentanil</a>, an ultrashort-acting opioid, is particularly useful for intubation while avoiding NMBAs. For a high-dose remifentanil intubation, the administration of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> (2 mg/kg) plus remifentanil (4 to 5 mcg/kg) provides good to excellent intubating conditions at 2.5 minutes after induction [<a href="#rid22">22</a>]. We give <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a> (10 mg IV) along with the propofol for this type of induction to avoid the profound bradycardia and hypotension that may result from this dose of remifentanil. This combination of medications can be used for rapid sequence induction.</p><p></p><p class="bulletIndent1">Other IV agents may be used to reduce the reflexes in response to laryngoscopy and intubation while avoiding the administration of NMBAs. IV <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> (1 to 1.5 mg/kg IV), small doses of short-acting opioids (eg, <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> 50 to 100 mcg), and <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a> (10 to 50 mg) can be given with induction. Use of both local anesthetics and beta blockers has been associated with worsening of myasthenic symptoms, so judicial use of these drugs is recommended. Intraoperative use of systemic lidocaine infusion is discussed below. (See <a class="local">'Medications that may exacerbate myasthenia gravis'</a> below.)</p><p></p><p class="headingAnchor" id="H697570641"><span class="h2">Neuromuscular blocking agents</span><span class="headingEndMark"> — </span>For most surgical procedures, administration of NMBAs is not necessary for patients with myasthenia. Adequate relaxation for surgery is often provided by the administration of the potent inhalation agents and, to a lesser extent, by the depth of anesthesia achieved with the use of IV agents. (See <a class="local">'Induction and maintenance of anesthesia'</a> above.)</p><p></p><p>As a general rule, we suggest caution in the use of NMBAs in patients with myasthenia. If NMBAs are necessary, we suggest the use of <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, and then reversal with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>. If sugammadex is unavailable, we avoid the use of NMBAs if at all possible. (See <a class="local">'Reversal of neuromuscular blocking agents'</a> below.)</p><p>Myasthenic patients, including those with only ocular MG and those in remission, have a variable, unpredictable response to administration of NMBAs compared with normal patients, as well as a variable response to NMBA reversal, including the possibility of cholinergic crisis [<a href="#rid23">23,24</a>]. They tend to be resistant to depolarizing NMBAs and very sensitive to nondepolarizing NMBAs. In addition, treatment with anticholinesterase medication affects the degree of relaxation and duration of action of NMBAs. If NMBAs are administered, the degree of neuromuscular blockade should optimally be assessed with a quantitative train-of-four nerve monitor, so that reversal to a train-of-four ratio (TOFR) &gt;0.9 can be verified. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Quantitative monitoring'</a>.)</p><p class="headingAnchor" id="H697570649"><span class="h3">Depolarizing neuromuscular blocking agents</span><span class="headingEndMark"> — </span>Patients with MG are resistant to neuromuscular blockade with depolarizing NMBAs (eg, <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>), possibly because they have a decreased number of acetylcholine receptors [<a href="#rid25">25,26</a>]. The 95 percent effective dose (ED<sub>95</sub>)<sub> </sub>of succinylcholine for patients with MG is 2.6 times that of normals (0.8 versus 0.3 mg/kg). Because succinylcholine is metabolized by plasma cholinesterase, treatment with anticholinesterase medication (eg, <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a>) may prolong the effect of succinylcholine [<a href="#rid27">27</a>].</p><p>Myasthenic patients are also at higher risk of development of phase II neuromuscular block (prolonged, unpredictable block with features of nondepolarizing block), especially with repeated doses of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Phase II block'</a>.)</p><p class="headingAnchor" id="H697570655"><span class="h3">Nondepolarizing neuromuscular blocking agents</span><span class="headingEndMark"> — </span>Patients with MG are extremely sensitive to nondepolarizing NMBAs (eg, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>). Very small doses and residual drug effect may result in respiratory distress or loss of airway protection after emergence from anesthesia. Nondepolarizing NMBAs should be administered in incremental, small doses of 0.1 to 0.2 times the ED<sub>95</sub>, titrated to effect and guided by the use of a quantitative train-of-four nerve monitor. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Quantitative monitoring'</a>.)</p><p>If the plan is to extubate the patient at the end of the anesthetic, we suggest the use of a steroidal NMBA (ie, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>) to allow reversal with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> rather than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>. (See <a class="local">'Reversal of neuromuscular blocking agents'</a> below.)</p><p>Mivacurium is a nondepolarizing NMBA that is metabolized by plasma cholinesterase. <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">Pyridostigmine</a> inhibits metabolism of mivacurium. Therefore, paralysis with mivacurium may be prolonged in patients who have taken pyridostigmine on the morning of surgery, though this effect is variable [<a href="#rid29">29,30</a>]. Mivacurium is no longer available in the United States or Canada, though it is available in other countries.</p><p class="headingAnchor" id="H3863533007"><span class="h3">Reversal of neuromuscular blocking agents</span><span class="headingEndMark"> — </span>When neuromuscular blockade is necessary, we suggest reversal of neuromuscular blockade with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> rather than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> for patients with MG. Reversal with sugammadex is not affected by anticholinesterase medication (unlike neostigmine) and sugammadex has been reported to predictably, rapidly, and safely reverse neuromuscular blockade with <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> in patients with MG.</p><p>Adequacy of reversal should be confirmed by a TOFR of &gt;0.9 using a quantitative train-of-four neuromuscular monitor. Subjective evaluation of the train-of-four with a standard, non-quantitative peripheral nerve stimulator is less reliable than quantitative monitoring and may provide inaccurate information for administration and reversal of NMBAs. Clinical measures (eg, five second head lift, vital capacity ≥15 mL/kg, strength of hand grip) are unreliable measures of neuromuscular reversal in any patient, including those with MG. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Quantitative monitoring'</a> and  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Clinical evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a><strong> </strong>– Sugammadex is a cyclodextrin medication that can be used to reverse neuromuscular blockade of the steroidal NMBAs (eg, <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> and <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>) by encapsulation of the NMBA molecule, without the need for anticholinesterase medication (see  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'</a>). Sugammadex 2 to 4 mg/kg IV has been reported to reverse moderate to deep vecuronium and rocuronium blockade in patients with MG within four minutes. Reversal with sugammadex is not affected by anticholinesterase medication and it has been reported to predictably, rapidly, and safely reverse neuromuscular blockade with rocuronium. There are several reported cases of failure of reversal of neuromuscular blockade with sugammadex and subsequent reversal with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> in patients with what was thought to be myasthenic crisis [<a href="#rid31">31-36</a>]. If after an appropriate dose of sugammadex the TOFR is &lt;0.9, a small dose of neostigmine may be considered, though the optimal dose of neostigmine in this setting is unclear. If reversal is still inadequate, the patient may require mechanical ventilation until the underlying problem (eg, myasthenic crisis, cholinergic crisis) is diagnosed and treated.</p><p></p><p class="bulletIndent1">In a retrospective database review that compared postoperative outcomes in over 1100 patients with MG who underwent thymectomy, postoperative complications were similar in patients who received <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> reversal versus no NMBA [<a href="#rid37">37</a>]. Conclusions from this study are limited by the lack of data on severity of MG, compounded by an exceedingly long hospital stay after thymectomy (median 19 and 25 days for patients who received rocuronium/sugammadex versus no NMBA, respectively).</p><p></p><p class="bulletIndent1">A retrospective study of patients who underwent thymectomy for myasthenia gravis found a decrease in myasthenic crisis in those patients receiving <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> over those who did not (4.3 versus 8.7 percent, odds ratio 0.48, 95% CI 0.25–0.91) [<a href="#rid38">38</a>]. Conclusions from this study are limited by the lack of data on the use of NMBAs or <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> in patients in the control group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">Neostigmine</a><strong> </strong>– Reversal of nondepolarizing NMBAs is unpredictable when using an anticholinesterase reversal agent (eg, neostigmine), especially for those patients who are taking anticholinesterase medication [<a href="#rid39">39</a>]. If <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> is unavailable, neostigmine should be titrated to effect to avoid cholinergic crisis. (See <a class="local">'Cholinergic crisis'</a> below.)</p><p></p><p class="headingAnchor" id="H697570667"><span class="h2">Medications that may exacerbate myasthenia gravis</span><span class="headingEndMark"> — </span>A number of other medications commonly administered in the operating room can affect neuromuscular transmission in some way.  (<a class="graphic graphic_table graphicRef100362" href="/d/graphic/100362.html" rel="external">table 3</a>) In normal patients, these effects are usually of no consequence, but in patients with MG, they can exacerbate muscle weakness, especially in the presence of residual anesthetic agents. When any of these medications is given in the operating room or the recovery room, the potential for respiratory or bulbar weakness should be considered.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – Several classes of antibiotics can affect neuromuscular transmission, including aminoglycosides [<a href="#rid40">40</a>] (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>) and polymyxins [<a href="#rid41">41</a>]. There are case reports of <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> (but not other penicillin-based antibiotics), macrolides [<a href="#rid42">42</a>] (eg, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, and fluoroquinolones [<a href="#rid43">43</a>] (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>) causing weakness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – Glucocorticoids are known to cause weakness, even though they are often used to treat MG. Thus, it would be prudent to avoid starting a glucocorticoid in the perioperative period to prevent this potential side effect, unless stress dose glucocorticoids are required. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local anesthetics</strong> – Whether to avoid the use of local anesthetics, particularly when administered intravenously, in patients with MG is unclear. Patients with MG do not appear to be at increased risk of complications if local anesthetics are used for local infiltration or regional anesthesia (ie, neuraxial anesthesia or peripheral nerve block), and in fact regional anesthesia techniques may be preferred when possible. (See <a class="local">'Choice of anesthetic technique'</a> above.)</p><p></p><p class="bulletIndent1">There is experimental evidence that IV local anesthetics in high doses may affect the neuromuscular junction and can potentiate the effects of neuromuscular blocking agents [<a href="#rid44">44-46</a>]. This has raised the possibility that IV local anesthetics could exacerbate MG, though there is little evidence that this occurs. There are older anecdotal reports of patients with exacerbation of myasthenia after administration of local anesthetics, though none in contemporary literature [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">IV <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> is commonly used intraoperatively, as a bolus during induction to suppress airway reflexes, and in some cases as an infusion as part of multimodal opioid sparing analgesia. The decision to use lidocaine in patients with MG should involve a risk-benefit analysis, considering the unknown but likely small risk of exacerbation of MG versus potential benefits, including reduced need for opioids. For most patients with myasthenia, the authors routinely administer an induction bolus of lidocaine, but avoid lidocaine infusion. (See <a class="local">'Induction and maintenance of anesthesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Other medications with the potential to exacerbate weakness include beta blockers, calcium channel blockers, antiepileptics (<a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>), phenothiazines, diuretics, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a> [<a href="#rid48">48</a>], magnesium, and opioids.</p><p></p><p class="headingAnchor" id="H371454236"><span class="h2">Extubation</span><span class="headingEndMark"> — </span>The anesthetic strategy for patients with MG should be designed to maximize the possibility of extubation at the end of surgery. Components of the plan include the use of short-acting anesthetics and multimodal analgesia to minimize opioid side effects, pulmonary toilet, and avoiding medications known to interfere with neuromuscular transmission.</p><p>Criteria for extubation should be similar to those for any patient having surgery, with proof of adequate ventilation and oxygenation, strength, and the ability to protect the airway, once objective confirmation of reversal of NMBAs is obtained, if used. (See <a class="local">'Reversal of neuromuscular blocking agents'</a> above.)</p><p class="headingAnchor" id="H697570673"><span class="h1">POSTOPERATIVE CONSIDERATIONS FOR PATIENTS WITH MYASTHENIA GRAVIS</span><span class="headingEndMark"> — </span>The need for postoperative monitoring and/or hospital admission for patients with MG should be individualized based on clinical features, the surgical procedure, the type of anesthetic, the intraoperative and immediate postoperative courses, and the need for postoperative care, including pain relief. Preoperative consultation with the patient's neurologist should include planning for postoperative care, the possibility of intensive care, and postoperative management of anticholinesterase medication. Chronic immunotherapies can be resumed when the patient is taking oral medications.</p><p>Ambulatory surgery can be considered for patients who have had minor surgical procedures, with monitored anesthesia care using short-acting sedatives, regional anesthesia, or general anesthesia either without neuromuscular blocking agents (NMBAs) or with NMBAs reversed with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>. Patients who develop any signs of bulbar or respiratory weakness in the recovery room should be admitted to the hospital for monitoring.</p><p class="headingAnchor" id="H371454361"><span class="h2">Myasthenic crisis</span><span class="headingEndMark"> — </span>Myasthenic crisis is defined as respiratory muscle and/or bulbar muscle weakness severe enough to necessitate intubation or to delay extubation after surgery. It can occur spontaneously with the stress of surgery, or as a result of a number of precipitants, including infection, residual anesthetics, withholding or tapering of MG medications, or any of a number of medications known to exacerbate MG. (See  <a class="medical medical_review" href="/d/html/5125.html" rel="external">"Myasthenic crisis", section on 'Precipitants'</a>.)</p><p>Myasthenic crisis must be distinguished from cholinergic crisis, another possible cause of weakness in patients with MG, as the treatment of the two conditions is very different. Formal neurophysiologic studies may be necessary and may provide more information, as excess cholinergic activity can be assessed, as well as cholinergic deficit. (See <a class="local">'Cholinergic crisis'</a> below.)</p><p>Myasthenic crisis may include weakness of respiratory and bulbar muscles. In awake patients, signs of impending crisis can include dysphagia, change in phonation, obstruction, weak cough, and difficulty handling secretions. Since the MG patient has a normal respiratory drive, the first sign of impending crisis may be an increase in respiratory rate with shallower tidal volume breaths [<a href="#rid49">49</a>]. Use of accessory muscles or paradoxical movement of the abdomen might be seen, even in patients who are still intubated at the end of surgery. Blood gases may initially show hypocapnia in spontaneously breathing patients. An increase in partial pressure of carbon dioxide (pCO<sub>2</sub>) is a sign of impending respiratory failure.</p><p>Treatment of myasthenic crisis should be coordinated with a neurologist. If weakness at the end of surgery suggests myasthenic crisis, delay of extubation is required, as well as intensive care. Urgent rapid therapy with plasma exchange or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) is often initiated, in addition to immunomodulating therapy. (See  <a class="medical medical_review" href="/d/html/5125.html" rel="external">"Myasthenic crisis", section on 'Management'</a>.)</p><p>Risk factors for postoperative myasthenic crisis after thymectomy are discussed above. (See <a class="local">'Prediction of postoperative myasthenic crisis'</a> above.)</p><p class="headingAnchor" id="H1946540"><span class="h2">Cholinergic crisis</span><span class="headingEndMark"> — </span>Patients who receive anticholinesterases are at risk for cholinergic crisis, which is manifested by paradoxical weakness along with other signs of cholinergic excess, such as those identified by the mnemonic "SLUDGE": salivation, lacrimation, urination, defecation, gastrointestinal distress, and emesis [<a href="#rid1">1</a>]. It happens rarely in patients outside the operating room but may occur after administration of an anticholinesterase for reversal of neuromuscular blockade in patients with MG [<a href="#rid50">50,51</a>]. In such cases, prolonged paralysis often results.</p><p>NMBAs should be avoided during anesthesia unless <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> (rather than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>) is available for reversal. (See <a class="local">'Neuromuscular blocking agents'</a> above.)</p><p>If cholinergic crisis is suspected, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> (0.4 to 2 mg IV) or <a class="drug drug_general" data-topicid="8496" href="/d/drug information/8496.html" rel="external">glycopyrrolate</a> (0.2 to 1 mg IV) should be administered, if not already given, to counteract muscarinic effects, and further anticholinesterase should be withheld. Repeated dosing of anticholinergic may be required.</p><p class="headingAnchor" id="H716168144"><span class="h1">OBSTETRIC ANESTHESIA</span><span class="headingEndMark"> — </span>Pregnant patients with MG should have antepartum anesthesia consultation. The plans for labor analgesia and anesthesia for potential instrumented or operative delivery should be determined well before the patient presents in labor. Like other surgical patients, obstetric patients should be assessed for the degree of bulbar dysfunction and respiratory muscle weakness, and also for the predicted ability to tolerate midthoracic levels of regional anesthetic block. Anesthesia concerns specific to labor and delivery include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Labor analgesia</strong> – Most patients require some degree of analgesia during labor. Neuraxial analgesia is the preferred method of pain control during labor for patients with MG because it reduces or eliminates the need for systemic opioid administration, thereby minimizing respiratory depression for patients with respiratory compromise. Excellent labor analgesia can be achieved with low levels of very dilute local anesthetic and opioid medications, which result in a minimal, if any, degree of motor block. (See  <a class="medical medical_review" href="/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)", section on 'Drug choice for neuraxial analgesia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Instrumented delivery</strong> – The first stage of labor depends on uterine smooth muscle and is unaffected by MG. However, the second stage of labor requires the use of striated muscle, which may weaken, increasing the need for instrumented delivery. Neuraxial analgesia can be augmented to provide adequate lumbosacral levels of anesthesia for forceps- or vacuum-assisted delivery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cesarean delivery – </strong>While neuraxial anesthesia (ie, spinal and epidural) is used most commonly for cesarean section, patients with MG may not tolerate the high level of block required. Neuraxial anesthesia results in both sensory and motor block; for cesarean section, a midthoracic level of anesthesia is required, which often affects the accessory muscles of respiration. For patients with significant bulbar or respiratory compromise, general anesthesia should be performed for cesarean section.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9245" href="/d/drug information/9245.html" rel="external">Chloroprocaine</a> is an ester local anesthetic commonly used for emergency epidural anesthesia for cesarean delivery; duration of action may be prolonged in patients who take cholinesterase inhibitors, though the extent to which this happens and the clinical relevance is unclear.</p><p></p><p class="headingAnchor" id="H697570705"><span class="h1">LAMBERT-EATON MYASTHENIC SYNDROME</span><span class="headingEndMark"> — </span>Lambert-Eaton myasthenic syndrome (LEMS) is a rare disorder of the neuromuscular junction, much less common than MG. It is often associated with small-cell lung cancer or other malignancies, but it can be associated with autoimmune processes as well. Patients with LEMS have muscle weakness caused by reduced acetylcholine release from presynaptic nerve terminals. Unlike MG, autonomic dysfunction is common with LEMS. Bulbar symptoms occur less commonly than with MG. Respiratory muscle weakness can rarely result in respiratory failure [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5134.html" rel="external">"Lambert-Eaton myasthenic syndrome: Treatment and prognosis"</a>.)</p><p>Anesthetic concerns for patients with LEMS include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with LEMS are very sensitive to <strong>both</strong> nondepolarizing and depolarizing neuromuscular blocking agents (NMBAs) [<a href="#rid53">53</a>], unlike patients with MG, who are resistant to depolarizing NMBAs and sensitive to nondepolarizing NMBAs. Patients with LEMS are more sensitive to nondepolarizing NMBAs than patients with MG, and reversal with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> may be ineffective [<a href="#rid54">54</a>]. We avoid NMBAs for patients with LEMS unless <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> is available for reversal. Patients who do receive NMBAs should receive small, titrated doses and should be monitored with an accelerometer and quantitative peripheral nerve stimulator whenever possible. (See <a class="local">'Neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with LEMS may be treated symptomatically with aminopyridines (eg, 3,4 Diaminopyridine) and anticholinesterases (eg, <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a>). Other treatments include immunologic therapy with intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG); oral immunosuppressive agents (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>); and, least commonly, plasma exchange or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See  <a class="medical medical_review" href="/d/html/5134.html" rel="external">"Lambert-Eaton myasthenic syndrome: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1">Patients should continue these medications up to the time of surgery, as there are case reports of respiratory insufficiency when medications were held prior to surgery [<a href="#rid55">55</a>]. Patients who chronically take glucocorticoids may require stress doses at the time of induction of anesthesia. (See <a class="local">'Myasthenia gravis treatments'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic dysfunction with LEMS may result in exaggerated hypotension with anesthesia induction agents and other vasodilators. A retrospective review of 60 anesthetics for patients with LEMS reported that hypotension occurred no more commonly in patients with autonomic dysfunction than in those without it, and all episodes of hypotension were treated easily with boluses of <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> or <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a> [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative concerns for patients with LEMS are similar to those for patients with MG.</p><p></p><p class="headingAnchor" id="H697570829"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative evaluation and management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with myasthenia gravis (MG), elective surgery should be performed during a stable phase of the disease and should be scheduled early in the day. (See <a class="local">'Preoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preoperative evaluation should include assessment of bulbar and respiratory symptoms. Pulmonary function testing (PFT) may be performed to establish a baseline and to help plan for postoperative care. (See <a class="local">'Preoperative pulmonary evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who take anticholinesterases (ie, <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a> or <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>), we suggest continuing the medication up to and including the morning of surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) to avoid respiratory and bulbar weakness if medication is withheld. Anticholinesterases can prolong the effect of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, delay the onset of nondepolarizing NMBAs, and make reversal of NMBAs with neostigmine unpredictable. (See <a class="local">'Anticholinesterase agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of anesthetic technique</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regional anesthesia should be used when possible. If general anesthesia is required, ultrashort- or short-acting sedatives, hypnotics, and anesthetic agents are preferred, to avoid postoperative respiratory depression. (See <a class="local">'Choice of anesthetic technique'</a> above and <a class="local">'Induction and maintenance of anesthesia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During neuraxial anesthesia, some patients may not tolerate the level of motor block required for the planned surgery, which may include accessory muscles of respiration (eg, cesarean delivery). (See <a class="local">'Obstetric anesthesia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preclinical evidence suggests that patients with MG may be at increased risk of exacerbation with administration of systemic local anesthetics, though there is little evidence that this occurs. For most patients with MG, the authors routinely administer an induction bolus of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, but avoid lidocaine infusion. Drugs that should be used with caution or avoided in patients with MG are shown in a table. (See <a class="local">'Medications that may exacerbate myasthenia gravis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular blocking agents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with MG are unpredictably resistant to depolarizing neuromuscular blocking agents (NMBAs) (eg, <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>) and unpredictably sensitive to nondepolarizing NMBAs (eg, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>). (See <a class="local">'Neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NMBAs are not necessary for most patients with MG. For patients who require neuromuscular block, we suggest using <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> to allow reversal with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Reversal with sugammadex (unlike <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>) is not affected by anticholinesterase medication and sugammadex has been reported to predictably, rapidly, and safely reverse neuromuscular blockade with rocuronium in patients with MG. (See <a class="local">'Reversal of neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent2">If <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> is not available, we avoid NMBAs unless absolutely necessary. (See <a class="local">'Nondepolarizing neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NMBAs should be used cautiously in patients with MG. Small doses of NMBA should be titrated to effect, guided by a quantitative neuromuscular monitor whenever possible. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Quantitative monitoring'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with MG who receive <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> or <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, we suggest reversal of neuromuscular blockade with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> rather than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Reversal of neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> must be used for reversal, it should be titrated to effect to avoid cholinergic crisis. (See <a class="local">'Reversal of neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adequacy of reversal should be confirmed by a train-of-four ratio (TOFR) of &gt;0.9 using a quantitative train-of-four neuromuscular monitor. (See <a class="local">'Reversal of neuromuscular blocking agents'</a> above and  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Reversal of neuromuscular block'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative care</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The need for postoperative monitoring and/or hospital admission for patients with MG should be individualized based on the clinical features, the risk factors for myasthenic crisis, the surgical procedure, the type of anesthetic, the intraoperative and immediate postoperative course, and the need for postoperative care. (See <a class="local">'Postoperative considerations for patients with myasthenia gravis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myasthenic crisis can be precipitated by surgery, administration of NMBAs, or any number of medications and conditions. Myasthenic crisis requires endotracheal intubation and ventilation, intensive care, and often rapid immunomodulating therapy. It should be distinguished from cholinergic crisis, which results from excessive administration of anticholinesterases and may also require ventilatory support. (See <a class="local">'Myasthenic crisis'</a> above and <a class="local">'Cholinergic crisis'</a> above and  <a class="medical medical_review" href="/d/html/5125.html" rel="external">"Myasthenic crisis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lambert-Eaton myasthenic syndrome</strong> – Unlike patients with MG, these patients are sensitive to both depolarizing and nondepolarizing NMBAs. Anesthesia concerns for patients with Lambert-Eaton myasthenic syndrome (LEMS) are otherwise similar to those for patients with MG. (See <a class="local">'Lambert-Eaton myasthenic syndrome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jamal BT, Herb K. Perioperative management of patients with myasthenia gravis: prevention, recognition, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107:612.</a></li><li><a class="nounderline abstract_t">Loach AB, Young AC, Spalding JM, Smith AC. Postoperative management after thymectomy. Br Med J 1975; 1:309.</a></li><li><a class="nounderline abstract_t">Leventhal SR, Orkin FK, Hirsh RA. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis. Anesthesiology 1980; 53:26.</a></li><li><a class="nounderline abstract_t">Lee HS, Lee HS, Lee HE, et al. Predictive factors for myasthenic crisis after videoscopic thymectomy in patients with myasthenia gravis. Muscle Nerve 2015; 52:216.</a></li><li><a class="nounderline abstract_t">Watanabe A, Watanabe T, Obama T, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 2004; 127:868.</a></li><li><a class="nounderline abstract_t">Lacomis D. Myasthenic crisis. Neurocrit Care 2005; 3:189.</a></li><li><a class="nounderline abstract_t">Gracey DR, Divertie MB, Howard FM Jr, Payne WS. Postoperative respiratory care after transsternal thymectomy in myasthenia gravis. A 3-year experience in 53 patients. Chest 1984; 86:67.</a></li><li><a class="nounderline abstract_t">Gritti P, Sgarzi M, Carrara B, et al. A standardized protocol for the perioperative management of myasthenia gravis patients. Experience with 110 patients. Acta Anaesthesiol Scand 2012; 56:66.</a></li><li><a class="nounderline abstract_t">Tripathi M, Kaushik S, Dubey P. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis. J Postgrad Med 2003; 49:311.</a></li><li><a class="nounderline abstract_t">Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine. Br J Anaesth 1987; 59:995.</a></li><li><a class="nounderline abstract_t">Dretchen KL, Morgenroth VH 3rd, Standaert FG, Walts LF. Azathioprine: effects on neuromuscular transmission. Anesthesiology 1976; 45:604.</a></li><li><a class="nounderline abstract_t">Glidden RS, Martyn JA, Tomera JF. Azathioprine fails to alter the dose-response curve of d-tubocurarine in rats. Anesthesiology 1988; 68:595.</a></li><li><a class="nounderline abstract_t">Dillon FX. Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 2004; 24:83.</a></li><li><a class="nounderline abstract_t">Katz JA, Murphy GS. Anesthetic consideration for neuromuscular diseases. Curr Opin Anaesthesiol 2017; 30:435.</a></li><li><a class="nounderline abstract_t">Nitahara K, Sugi Y, Higa K, et al. Neuromuscular effects of sevoflurane in myasthenia gravis patients. Br J Anaesth 2007; 98:337.</a></li><li><a class="nounderline abstract_t">Gissen AJ, Karis JH, Nastuk WL. Effect of halothane on neuromuscular transmission. JAMA 1966; 197:770.</a></li><li><a class="nounderline abstract_t">Rowbottom SJ. Isoflurane for thymectomy in myasthenia gravis. Anaesth Intensive Care 1989; 17:444.</a></li><li><a class="nounderline abstract_t">Kiran U, Choudhury M, Saxena N, Kapoor P. Sevoflurane as a sole anaesthetic for thymectomy in myasthenia gravis. Acta Anaesthesiol Scand 2000; 44:351.</a></li><li><a class="nounderline abstract_t">Della Rocca G, Coccia C, Diana L, et al. Propofol or sevoflurane anesthesia without muscle relaxants allow the early extubation of myasthenic patients. Can J Anaesth 2003; 50:547.</a></li><li><a class="nounderline abstract_t">Baftiu N, Hadri B, Morina M, Mustafa A. Anesthesia for trans-sternal thymectomy: modified non-muscle relaxant technique. Med Arh 2011; 65:317.</a></li><li><a class="nounderline abstract_t">Lorimer M, Hall R. Remifentanil and propofol total intravenous anaesthesia for thymectomy in myasthenia gravis. Anaesth Intensive Care 1998; 26:210.</a></li><li><a class="nounderline abstract_t">Bennett JA, Abrams JT, Van Riper DF, Horrow JC. Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure. Anesthesiology 1997; 87:1070.</a></li><li><a class="nounderline abstract_t">Baraka A, Afifi A, Muallem M, et al. Neuromuscular effects of halothane, suxamethonium and tubocurarine in a myasthenic undergoing thymectomy. Br J Anaesth 1971; 43:91.</a></li><li><a class="nounderline abstract_t">Abel M, Eisenkraft JB, Patel N. Response to suxamethonium in a myasthenic patient during remission. Anaesthesia 1991; 46:30.</a></li><li><a class="nounderline abstract_t">Eisenkraft JB, Book WJ, Mann SM, et al. Resistance to succinylcholine in myasthenia gravis: a dose-response study. Anesthesiology 1988; 69:760.</a></li><li><a class="nounderline abstract_t">Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973; 182:293.</a></li><li><a class="nounderline abstract_t">Baraka A. Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase. Anaesthesia 1992; 47:217.</a></li><li><a class="nounderline abstract_t">Baraka A, Baroody M, Yazbeck V. Repeated doses of suxamethonium in the myasthenic patient. Anaesthesia 1993; 48:782.</a></li><li><a class="nounderline abstract_t">Gitlin MC, Jahr JS, Margolis MA, McCain J. Is mivacurium chloride effective in electroconvulsive therapy? A report of four cases, including a patient with myasthenia gravis. Anesth Analg 1993; 77:392.</a></li><li><a class="nounderline abstract_t">Paterson IG, Hood JR, Russell SH, et al. Mivacurium in the myasthenic patient. Br J Anaesth 1994; 73:494.</a></li><li><a class="nounderline abstract_t">de Boer HD, Shields MO, Booij LH. Reversal of neuromuscular blockade with sugammadex in patients with myasthenia gravis: a case series of 21 patients and review of the literature. Eur J Anaesthesiol 2014; 31:715.</a></li><li><a class="nounderline abstract_t">Vymazal T, Krecmerova M, Bicek V, Lischke R. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases. Ther Clin Risk Manag 2015; 11:1593.</a></li><li><a class="nounderline abstract_t">Carron M, De Cassai A, Linassi F. Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations. Ann Transl Med 2019; 7:S307.</a></li><li><a class="nounderline abstract_t">Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis. Anaesthesia 2010; 65:302.</a></li><li><a class="nounderline abstract_t">Rudzka-Nowak A, Piechota M. Anaesthetic management of a patient with myasthenia gravis for abdominal surgery using sugammadex. Arch Med Sci 2011; 7:361.</a></li><li><a class="nounderline abstract_t">Fernandes HDS, Ximenes JLS, Nunes DI, et al. Failure of reversion of neuromuscular block with sugammadex in patient with myasthenia gravis: case report and brief review of literature. BMC Anesthesiol 2019; 19:160.</a></li><li><a class="nounderline abstract_t">Tsukada S, Shimizu S, Fushimi K. Rocuronium reversed with sugammadex for thymectomy in myasthenia gravis: A retrospective analysis of complications from Japan. Eur J Anaesthesiol 2021; 38:850.</a></li><li><a class="nounderline abstract_t">Mouri H, Jo T, Matsui H, et al. Effect of Sugammadex on Postoperative Myasthenic Crisis in Myasthenia Gravis Patients: Propensity Score Analysis of a Japanese Nationwide Database. Anesth Analg 2020; 130:367.</a></li><li><a class="nounderline abstract_t">Baraka A. Anesthesia and critical care of thymectomy for myasthenia gravis. Chest Surg Clin N Am 2001; 11:337.</a></li><li><a class="nounderline abstract_t">Harnett MT, Chen W, Smith SM. Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness. Neuropharmacology 2009; 57:502.</a></li><li><a class="nounderline abstract_t">Decker DA, Fincham RW. Respiratory arrest in myasthenia gravis with colistimethate therapy. Arch Neurol 1971; 25:141.</a></li><li><a class="nounderline abstract_t">Cadisch R, Streit E, Hartmann K. [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)]. Schweiz Med Wochenschr 1996; 126:308.</a></li><li><a class="nounderline abstract_t">Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 2011; 34:839.</a></li><li><a class="nounderline abstract_t">MATTHEWS EK, QUILLIAM JP. EFFECTS OF CENTRAL DEPRESSANT DRUGS UPON ACETYLCHOLINE RELEASE. Br J Pharmacol Chemother 1964; 22:415.</a></li><li><a class="nounderline abstract_t">Hirst GD, Wood DR. On the neuromuscular paralysis produced by procaine. Br J Pharmacol 1971; 41:94.</a></li><li><a class="nounderline abstract_t">Katz RL, Gissen AJ. Effects of intravenous and intra-arterial procaine and lidocaine on neuromuscular transmission in man. Acta Anaesthesiol Scand Suppl 1969; 36:103.</a></li><li><a class="nounderline abstract_t">Howard JF Jr. Adverse drug effects on neuromuscular transmission. Semin Neurol 1990; 10:89.</a></li><li><a class="nounderline abstract_t">Godley PJ, Morton TA, Karboski JA, Tami JA. Procainamide-induced myasthenic crisis. Ther Drug Monit 1990; 12:411.</a></li><li><a class="nounderline abstract_t">Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 2004; 24:75.</a></li><li><a class="nounderline abstract_t">Kim JM, Mangold J. Sensitivity to both vecuronium and neostigmine in a sero-negative myasthenic patient. Br J Anaesth 1989; 63:497.</a></li><li><a class="nounderline abstract_t">Rolbin WH, Levinson G, Shnider SM, Wright RG. Anesthetic considerations for myasthenia gravis and pregnancy. Anesth Analg 1978; 57:441.</a></li><li><a class="nounderline abstract_t">Smith AG, Wald J. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Neurology 1996; 46:1143.</a></li><li><a class="nounderline abstract_t">Small S, Ali HH, Lennon VA, et al. Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. Anesthesiology 1992; 76:142.</a></li><li><a class="nounderline abstract_t">Brown JC, Charlton JE. A study of sensitivity to curare in myasthenic disorders using a regionaltechnique. J Neurol Neurosurg Psychiatry 1975; 38:27.</a></li><li><a class="nounderline abstract_t">Weingarten TN, Araka CN, Mogensen ME, et al. Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients. J Clin Anesth 2014; 26:648.</a></li></ol></div><div id="topicVersionRevision">Topic 94256 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19426917" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Perioperative management of patients with myasthenia gravis: prevention, recognition, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1111793" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Postoperative management after thymectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7386905" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prediction of the need for postoperative mechanical ventilation in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25470186" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predictive factors for myasthenic crisis after videoscopic thymectomy in patients with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001919" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377829" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Myasthenic crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6734295" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Postoperative respiratory care after transsternal thymectomy in myasthenia gravis. A 3-year experience in 53 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092037" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A standardized protocol for the perioperative management of myasthenia gravis patients. Experience with 110 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699228" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888477" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/185925" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Azathioprine: effects on neuromuscular transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3354895" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Azathioprine fails to alter the dose-response curve of d-tubocurarine in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229795" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anesthesia issues in the perioperative management of myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448298" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anesthetic consideration for neuromuscular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251207" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neuromuscular effects of sevoflurane in myasthenia gravis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5953370" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of halothane on neuromuscular transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2556947" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Isoflurane for thymectomy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10714854" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sevoflurane as a sole anaesthetic for thymectomy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12826544" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Propofol or sevoflurane anesthesia without muscle relaxants allow the early extubation of myasthenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22073861" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anesthesia for trans-sternal thymectomy: modified non-muscle relaxant technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9564405" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Remifentanil and propofol total intravenous anaesthesia for thymectomy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366458" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Difficult or impossible ventilation after sufentanil-induced anesthesia is caused primarily by vocal cord closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4324539" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Neuromuscular effects of halothane, suxamethonium and tubocurarine in a myasthenic undergoing thymectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996750" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Response to suxamethonium in a myasthenic patient during remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3189923" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Resistance to succinylcholine in myasthenia gravis: a dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4742736" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314525" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214497" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Repeated doses of suxamethonium in the myasthenic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346843" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Is mivacurium chloride effective in electroconvulsive therapy? A report of four cases, including a patient with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7999490" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mivacurium in the myasthenic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25192270" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reversal of neuromuscular blockade with sugammadex in patients with myasthenia gravis: a case series of 21 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26508869" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016026" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105151" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The use of sugammadex in a patient with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22291783" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anaesthetic management of a patient with myasthenia gravis for abdominal surgery using sugammadex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31421671" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Failure of reversion of neuromuscular block with sugammadex in patient with myasthenia gravis: case report and brief review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34226417" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rocuronium reversed with sugammadex for thymectomy in myasthenia gravis: A retrospective analysis of complications from Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31124838" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of Sugammadex on Postoperative Myasthenic Crisis in Myasthenia Gravis Patients: Propensity Score Analysis of a Japanese Nationwide Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11413760" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Anesthesia and critical care of thymectomy for myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646457" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5571015" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Respiratory arrest in myasthenia gravis with colistimethate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8701248" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21879778" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14190477" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : EFFECTS OF CENTRAL DEPRESSANT DRUGS UPON ACETYLCHOLINE RELEASE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4396131" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : On the neuromuscular paralysis produced by procaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4315659" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of intravenous and intra-arterial procaine and lidocaine on neuromuscular transmission in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2161128" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adverse drug effects on neuromuscular transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2396315" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Procainamide-induced myasthenic crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229794" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Myasthenia gravis: management of myasthenic crisis and perioperative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2573388" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sensitivity to both vecuronium and neostigmine in a sero-negative myasthenic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/568405" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Anesthetic considerations for myasthenia gravis and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780107" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1309626" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1117298" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A study of sensitivity to curare in myasthenic disorders using a regionaltechnique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25468580" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
